All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): bacTRL-Spike vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
The study will evaluate safety and preliminary evidence of immunogenicity to SARS CoV-2 elicited by bacTRL-Spike™ among healthy volunteers. Preliminary data are anticipated in early 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): bacTRL-Spike vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: National Research Council Industrial Research Assistance Program
Deal Size: $2.8 million Upfront Cash: Undisclosed
Deal Type: Funding October 20, 2020
Details:
The funding follows a notification Symvivo received from the Government of Canada indicating it had reviewed Symvivo’s proposal and its bacTRL-Spike™ vaccine candidate had met the required scientific and technical thresholds for funding.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OB-002
Therapeutic Area: Infections and Infectious Diseases Product Name: OB-002
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
The Phase 1 study design included open-label single-dose (vaginal and rectal) and multi-dose product (vaginal) administration of OB-002H gel to study participants followed by a randomised, double-blind, placebo-controlled multi-dose (vaginal) phase of product administration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2020
Details:
The Phase I clinical trial is a randomized, partially blinded study of 180 normal healthy subjects and will evaluate dosages of 3.75, 7.5 or 15 micrograms of the recombinant CoVLP vaccine candidate alone or with an adjuvant in a prime-boost regimen.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Infections and Infectious Diseases Product Name: FSD201
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
FSD Pharma announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): bacTRL-Spike
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2020
Details:
Symvivo disclosed it was recruiting up to 84 participants for an observed-blinded Phase I clinical trial to evaluate the safety, tolerability and immunogenicity of its bacTRL-Spike.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATI-2307
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Details:
The presentation will highlight Appili’s ATI-2307 program, a novel antifungal for resistant infections that the Company acquired from FUJIFILM Toyama Chemical in 2019.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
